Related Experiment Video
Updated: Aug 26, 2025
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.1K
[Clostridioides difficile infection: various therapeutic approaches].
Marion Meuwly1, Christian Chuard2
1Service de médecine interne, Hôpital fribourgeois, 1708 Fribourg.
Revue Medicale Suisse
|October 13, 2022
Summary
New guidelines recommend fidaxomicin for Clostridioides difficile colitis, but Swiss recommendations differ. Metronidazole remains a viable first-line option in Switzerland for specific patient groups.
Area of Science:
- Infectious Diseases
- Microbiology
- Clinical Practice Guidelines
Background:
- Recent 2021 guidelines from European and American Infectious Diseases Societies recommend fidaxomicin as first-line treatment for Clostridioides difficile colitis.
- Vancomycin is suggested as a second-line option, with metronidazole reserved for cases where other treatments are unavailable.
Purpose of the Study:
- To evaluate the discrepancy in treatment recommendations for Clostridioides difficile colitis between international guidelines and the Swiss Infectious Diseases Society.
- To assess the continued appropriateness of metronidazole as a first-line treatment in the Swiss context.
Main Methods:
- Comparative analysis of international and national treatment guidelines.
- Review of Clostridioides difficile strains prevalent in Switzerland.
- Consideration of patient risk factors and relapse probability.
Main Results:
- The Swiss Infectious Diseases Society has not endorsed the new international guidelines.
- Metronidazole is still proposed as a first-line treatment by the Swiss Society.
- Metronidazole demonstrates satisfactory efficacy against Swiss Clostridioides difficile strains in patients without risk factors and with a low probability of relapse.
Conclusions:
- Metronidazole remains a cost-effective and efficacious first-line treatment for Clostridioides difficile colitis in specific patient populations in Switzerland.
- Divergent treatment recommendations highlight the importance of local epidemiological data and patient characteristics in guiding therapy.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
172
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
172
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
250
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
250
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
192
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
192
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
189
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
189
01:17Drugs for Treatment of Diarrhea-Predominant IBS
268
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
268
01:29Drugs for Treatment of Ulcerative Colitis in IBD
225
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
225